UNSPSC 51161554: Ritolukast

This classification denotes an anti-asthmatic agent with the molecular formula C17H13F3N2O3S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 0E8R4GDE2Q, chemically known as 1,1,1-trifluoro-alpha-2-quinolylmethanesulfon-m-anisidide but generally known as ritolukast, which bears US NIH Compound Identifier 60539. European Medicines Agency schedules Ritolukast in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10341MIG.

UNSPSC 51161554 Ritolukast, a Commodity code, covers pharmaceutical supply arrangements where state and local governments and their cooperative purchasing vehicles source branded or generic pharmaceutical products through wholesaler distribution networks. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, represents the primary recent issuing body under this code, procuring generic multi-source pharmaceuticals and over-the-counter products for distribution across participating state and local government facilities in Minnesota and Oregon. State and local buyers under this code typically work through established wholesaler networks—in the MMCAP case, AmerisourceBergen Drug Corporation (Cencara), Cardinal Health 110 and 112, and Morris & Dickson Co., LLC—rather than purchasing directly from manufacturers. Vendors must hold current Good Manufacturing Practice (cGMP) and Drug Supply Chain Security Act (DSCSA) certifications, maintain contractual relationships with at least two of three authorized wholesalers with chargeback systems in place, and carry substantial insurance including commercial general liability of $5,000,000 per occurrence and network security and privacy liability of $2,000,000. Products must be FDA-compliant with expiration dates at least one year from manufacture and a minimum six-month shelf life.

MMCAP's RFP for generic multi-source pharmaceuticals and OTC products posted January 20, 2026, with proposals due March 26, 2026, represents the primary recent state-local activity under the code. The solicitation emphasizes price competitiveness (weighted at 75 percent of evaluation), fixed pricing for the contract term (10 percent), compliance with administrative fee data format and EDI capability requirements (5 percent each), and agreement to a 3 percent administrative fee (5 percent). Contract awards take effect July 1, 2026, with terms of two years for new responders and optional extensions at MMCAP's discretion; incumbent responders' amendments align with existing agreement expiration dates through June 30, 2028. Vendors must submit detailed product information including National Drug Codes (NDC), SKUs, UPCs, generic descriptions, strength, dosage form, trade names, packaging configurations, and manufacturing locations via the ePro procurement system, with pricing in designated Excel spreadsheet format converted to CSV. No specific set-aside designations or restrictions for disadvantaged enterprises are disclosed in the solicitation.